Business Context and Reporting Period
This Form 8-K was filed by Oncobiologics, Inc. (noted as Outlook Therapeutics, Inc. in metadata) on October 24, 2018. The report addresses a critical corporate governance event regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on compliance with Nasdaq listing rules rather than financial performance metrics.
Material Changes
The primary material change is the receipt of written notice from Nasdaq Staff on October 24, 2018, determining that the Company's securities will be delisted. This determination is based on the Company's continued failure to meet the minimum $1.00 bid price requirement (Nasdaq Listing Rule 5550(a)(2)) as of October 23, 2018. This follows a 180-day grace period that began after the bid price closed below $1.00 for 30 consecutive business days ending April 25, 2018.
Outlook, Risks, and Management Commentary
- Management Action: The Company intends to request a hearing before the Nasdaq Hearings Panel to seek an extension to regain compliance. This request will stay any delisting action pending the hearing's outcome.
- Compliance Strategy: The Company plans to take definitive steps to meet the bid price requirement, potentially implementing a reverse stock split. Stockholders approved the potential for a reverse stock split on September 21, 2018.
- Risks and Contingencies: There is no assurance that the Panel will grant the request for continued listing or that the Company will successfully evidence compliance within any granted extension period.
Investor Verification Checklist
- Verify the current status of the Company's request for a hearing before the Nasdaq Hearings Panel.
- Confirm whether the Board of Directors has formally authorized a reverse stock split to address the bid price deficiency.
- Monitor the Company's stock bid price to determine if it has sustained a level above $1.00 per share.
- Check for subsequent filings regarding the outcome of the Nasdaq hearing or any final delisting notices.